Literature DB >> 8958601

Acute phase proteins in male Chinese schizophrenic patients in Singapore.

C T Wong1, W F Tsoi, N Saha.   

Abstract

Changes in the concentration of some serum acute phase proteins (alpha 1-antitrypsin, alpha 2-macroglobulin, complement C3, haptoglobin, ceruloplasmin, transferrin, albumin and hemopexin), thyroxine-binding globulin, retinol-binding globulin, plasminogen and Gc-globulin are reported in two separate series of Chinese, male schizophrenic patients and healthy controls. In the first series, 41 healthy blood donors and 98 schizophrenic patients in different stages of the disease were investigated. The second series consists of a random sample of 50 acutely ill schizophrenic patients and a second group of healthy subjects. The concentrations of these serum proteins were measured by rocket immunoelectrophoresis in agarose gel. Increased levels of serum alpha 1-antitrypsin, alpha 2-macroglobulin, haptoglobin, ceruloplasmin, and thyroxine-binding globulin were observed in both series of patients when compared to their respective controls. Albumin, transferrin and retinol-binding protein levels were reduced in patients in both series. Hemopexin levels were increased only in the acutely ill patients while complement C3 was decreased in the chronically ill patients. No changes were observed in the Gc-globulin levels of all groups of patients. With the exception of complement C3, the changes observed in the levels of these serum proteins were appropriate for that of an acute phase response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958601     DOI: 10.1016/s0920-9964(96)00037-0

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

Review 1.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

Review 2.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 3.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

4.  Haptoglobin in ultra-high risk of psychosis - Findings from the longitudinal youth at risk study (LYRIKS).

Authors:  Jie Yin Yee; Si Qing Chow; Keane Lim; Wilson Goh; Judy Sng; Tih-Shin Lee; Jimmy Lee
Journal:  Brain Behav Immun Health       Date:  2022-06-12

5.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

6.  Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.

Authors:  Jason D Cooper; Sureyya Ozcan; Renee M Gardner; Nitin Rustogi; Susanne Wicks; Geertje F van Rees; F Markus Leweke; Christina Dalman; Håkan Karlsson; Sabine Bahn
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

7.  Peripheral immune markers and antipsychotic non-response in psychosis.

Authors:  Daniela Enache; Naghmeh Nikkheslat; Dina Fathalla; B Paul Morgan; Shôn Lewis; Richard Drake; Bill Deakin; James Walters; Stephen M Lawrie; Alice Egerton; James H MacCabe; Valeria Mondelli
Journal:  Schizophr Res       Date:  2021-03-02       Impact factor: 4.662

8.  Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.

Authors:  Brian Dean
Journal:  Schizophr Res Treatment       Date:  2011-06-18

9.  Neonatal levels of acute phase proteins and later risk of non-affective psychosis.

Authors:  R M Gardner; C Dalman; S Wicks; B K Lee; H Karlsson
Journal:  Transl Psychiatry       Date:  2013-02-19       Impact factor: 6.222

10.  A Preliminary Genetic Analysis of Complement 3 Gene and Schizophrenia.

Authors:  Jianliang Ni; Shuangfei Hu; Jiangtao Zhang; Wenxin Tang; Weihong Lu; Chen Zhang
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.